Voices

Giannis Mountzios: Discussing the Role of STK11/KEAP1/KRAS Mutations in Immune Modulation in NSCLC

IASLC/X

Aug 20, 2025, 18:07

Giannis Mountzios: Discussing the Role of STK11/KEAP1/KRAS Mutations in Immune Modulation in NSCLC

Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X by the International Association for the Study of Lung Cancer (IASLC), adding:

“It was my great pleasure discussing the role of STK11/KEAP1/KRAS mutations in immune modulation in NSCLC. Thank you, Narjust Florez, for making us feel so cozy, and my dear colleague Biagio Ricciuti for great discussions. Thankful to IASLC for the voice.”

Quoting IASLC’s post:

“On a new episode of Lung Cancer Considered, host Narjust Florez talks with Biagio Ricciuti and Giannis Mountzios about resistance to immune checkpoint inhibitors, STK11/KEAP1/KRAS co-mutations, and emerging NSCLC. therapeutics.

Listen.”

More posts featuring Giannis Mountzios and IASLC.

Biagio Ricciuti cancer Giannis Mountzios IASLC International Association for the Study of Lung Cancer Lung cancer Narjust Florez NSCLC OncoDaily Oncology

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth